Right Upper Quadrant Screening in Hepatitis C Patients
Patients with hepatitis C and compensated cirrhosis require ultrasound of the liver conducted within the prior 6 months as part of pretreatment assessment to exclude hepatocellular carcinoma (HCC) and subclinical ascites. 1
Screening Protocol Based on Cirrhosis Status
Patients WITH Cirrhosis (Compensated)
Pretreatment ultrasound screening is mandatory:
- Liver ultrasound must be performed within 6 months prior to initiating HCV treatment 1
- The primary purpose is to exclude HCC and detect subclinical ascites 1
- This applies to all treatment-naive patients with compensated cirrhosis (Child-Pugh A) 1
Ongoing HCC surveillance after achieving cure:
- Patients with cirrhosis require lifelong HCC surveillance even after sustained virologic response (SVR) 2, 3
- Ultrasound examination of the liver every 6 months is the recommended screening modality 2
- Combined use of ultrasound with alpha-fetoprotein (AFP) increases sensitivity while decreasing specificity and represents a reasonable option 2
- This surveillance should continue indefinitely as cirrhosis persists despite viral cure 4, 3
Patients WITHOUT Cirrhosis
No routine ultrasound screening is required:
- The AASLD/IDSA guidelines do not mandate pretreatment ultrasound for non-cirrhotic patients 1
- Cirrhosis assessment is performed using FIB-4 score and other noninvasive methods rather than imaging 1
- After achieving SVR in the absence of cirrhosis, no liver-related imaging follow-up is recommended 3
Determining Cirrhosis Status
Multiple noninvasive methods can identify cirrhosis without requiring ultrasound initially:
- FIB-4 score >3.25 suggests cirrhosis 1
- Transient elastography (FibroScan) stiffness >12.5 kPa indicates cirrhosis 1
- Clinical evidence including liver nodularity and/or splenomegaly on imaging, or platelet count <150,000/mm³ 1
- Noninvasive serologic tests above proprietary cutoffs (FibroSure, Enhanced Liver Fibrosis Test) 1
Critical Pitfalls to Avoid
Do not skip pretreatment ultrasound in cirrhotic patients:
- Known or suspected HCC is an absolute contraindication to simplified treatment protocols 1
- Detecting HCC before treatment initiation fundamentally changes management 1
- Subclinical ascites may indicate more advanced disease than clinically apparent 1
Do not discontinue HCC surveillance after viral cure:
- The risk of HCC persists in patients with cirrhosis even after achieving SVR 2, 3
- Screening must continue every 6 months indefinitely 2, 4
- This is a common error as patients and providers may assume cure eliminates all risk 3
Post-Treatment Monitoring
For patients with cirrhosis who achieve SVR:
- Abdominal ultrasonography (with or without AFP) every 6 months for HCC surveillance 3
- Upper endoscopy every 2-3 years for esophageal varices screening 3
- Assessment for disease progression every 6-12 months with hepatic function panel, CBC, and INR if unable to be retreated 1
For patients without cirrhosis who achieve SVR: